Kornimate/medical-research-clean huggingface dataset:
supervised exercise, sleep in patients with non metastatic breast cancer

Conditions: Breast Cancer

Summary: insomnia affects about 60% of the patients treated with radio-chemotherapy, a percentage twice higher compared to that observed in the general population. this sleep disorder increases cancer-related fatigue (crf), the side effect most often reported by patients. conversely, it is well accepted that adapted physical activity (apa) improves tolerance to treatment, decreases the risk of recurrence, increases survival, and reduces crf. the present study aims to evaluate, in non-metastatic breast cancer patients, the composition and architecture of sleep by ambulatory polysomnography and to verify the effects of an apa rehabilitation program (3 times a week during 12 weeks), on the quality and quantity of sleep, daytime sleepiness. the biological markers: melatonin and body temperature will be studied to better understand the chronobiological mechanisms of the sleep-wake rhythm. finally, the physiological responses to exercise, pain, crf and finally quality of life will be studied at the beginning, at the end of the program and at a distance from it. improved sleep-wake rhythm by a physical activity may reduce crf, prevent recurrence and comorbidities.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 65 * patients with non-metastatic breast cancer undergoing chemotherapy * patients with insomnia * certificate of non-contraindication to the practice of physical activity * women who have been postmenopausal for at least 24 months, surgically sterilized, or, for women of childbearing potential, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches) * signature of informed consent to participate indicating that the subject has understood the purpose and procedures required by the study and that he agrees to participate in the study and to comply with the requirements and restrictions inherent in this study * affiliation to a french social security scheme or beneficiary of such a scheme. exclusion criteria: * patients treated with melatonin or taking hypnotics * patients with metastases * oxygen saturation at rest (sao2) ≤ 92% * patients without insomnia and / or sleep disorders * autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis) * symptomatic osteoarthritis, cardiovascular disease (angina pectoris or uncontrolled hypertension) or lung disease (chronic obstructive pulmonary disease) * patients suffering from malnutrition (bmi \ 10% during the previous 3 months * patients with psychiatric or cognitive disorders deemed unsuitable for physical activity * pregnant or breastfeeding women * legal incapacity or limited legal capacity * subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator * subject without health insurance * subject being in the period of exclusion from another study or provided for by the "national file of volunteers".
disparities among liver transplant patients

Conditions: End Stage Liver DIsease

Summary: the purpose of this study is to inform healthcare interventions to reduce the disparities in liver transplant listing and in transplantation.

aim 1. establish a longitudinal cohort of patients with end-stage liver dysfunction. aim 2. examine interpersonal and structural factors associated with liver transplant evaluation and listing by patient characteristics (e.g., race, ethnicity, ses, gender). aim 3. examine the use of stigmatizing language among patients undergoing liver transplant based on their demographic characteristics (e.g., race, ethnicity, ses, gender).

Eligibility criteria:
inclusion criteria: - patients with end-stage liver, kidney, or cardiac dysfunction. exclusion criteria: * patients with more than one system with end stage organ dysfunction, dementia, cognitive or sensory impairment, prior solid organ transplant. * patients with potential medical exclusions for transplant.

Keywords: transplants transplantation healthcare disparities minority health communication
mindfulness based stress reduction for high blood pressure

Conditions: Hypertension

Summary: nearly 60 million adults in the united states have high blood pressure (bp) in the pre-hypertension (sbp 120-139 or dbp 80-89). hypertension is estimated to account for 1 in 8 deaths in the world, and in the us the direct and indirect costs of high bp are estimated to reach $59.7 billion in 2005. jnc-7 guidelines recommend lifestyle modifications for prehypertension, followed by antihypertensive medication if bp progresses to stage i hypertension. mindfulness-based stress reduction (mbsr) is an increasingly popular practice that has been purported to alleviate stress and treat certain health conditions. some stress management therapies and one meditation therapy (e.g., transcendental meditation) have shown promise in reducing elevated bp, but mbsr has not been evaluated as a treatment for high bp. when added to lifestyle modification advice, mbsr may be an appropriate complementary treatment for prehypertension. however, prior to a large randomized clinical trial of mbsr for prehypertension and/or hypertension, pilot data is necessary to provide preliminary evidence of a treatment effect and to evaluate feasibility. this feasibility randomized clinical trial of mbsr for unmedicated prehypertension will provide preliminary evidence to support a larger randomized clinical trial by evaluating the feasibility and safety of mbsr as a complementary treatment for high bp and by documenting any treatment effect. sixty patients with unmedicated bp in the range of sbp 120-139 mm hg or dbp 80-89 mm hg will be randomly assigned to mbsr or a progressive muscle relaxation control condition. all patients will receive lifestyle modification advice. patients will complete 8 weeks of mbsr delivered in a group format by an experienced psychologist trained in mbsr or 8 weeks of progressive muscle relaxation training matched for therapist contact and homework. patients bp will be assessed prior to randomization and following treatment by researchers blind to treatment assignment. accrual rates, acceptance of randomization, treatment adherence, treatment fidelity, and patient satisfaction with treatment will be evaluated.

see brief summary

Eligibility criteria:
inclusion criteria: * prehypertension * 30-60 years of age exclusion criteria: * normal bp * hypertension * pregnancy * smoking * use of antihypertensive medication
language stimuli screening in children

Conditions: Language Disorder; Healthy

Summary: this study will determine baseline language skills in children 4 to 8 years old. the data will be used to design studies using functional magnetic resonance imaging (fmri) to identify what areas of the brain in children are involved in understanding language. this information is important for children who require brain surgery to control seizures. healthy normal volunteers between the ages of 4 and 8 years who have an iq of 70 or more; who have no history of neurologic, psychiatric or language disorder; who are performing at or above grade level, and who are native english speakers may be eligible for this study. participants will be asked to do the following: * name pictures or read words that appear on a computer screen * listen to stories and answer questions about them * match pictures to a spoken word the children's responses will be recorded.

we propose to study normal children to establish baseline data to use to develop novel sets of stimuli for functional imaging paradigms. tasks using these stimuli will include object naming, sentence comprehension, and single word reading.

Eligibility criteria:
inclusion criteria: children will be between the ages 4 and 8 are eligible. exclusion criteria: children who meet one of the following criteria are not eligible: iq below 70; history of neurologic or psychiatric disorders; history of an language disorder; performing below grade-level; non-native english speaker.

Keywords: reading naming
flexible urs in management of renal stones in anomalous kidney

Conditions: Endourology; Stones, Kidney; Laser; Congenital Disorders; Horseshoe Kidney; Malrotation of Kidney; Ectopic Kidney

Summary: the urotheliasis is a common problem encountered daily by all urologists worldwide with rates up to 13% in north america, 9% in europe and 5% in asia . the urotheliasis is treated by conservation, medical treatment and surgery according to many factors . anomalies in the kidney happens due to failure in ascending , fusion, rotation or all together, horse-shoe kidney is the most common example , found in one of 400 patients . pcnl and urs are the golden standard method for stone extraction worldwide, since their introduction 1975 by fernstrom and johansson \& arthur smith respectively in normal kidney .since the development of the endourological procedures and instrument , continuous updates and upgrades have been applied ,such as enhancing the optical systems ,reducing the diameter, navigation (deflection angles) and stone fragmentation .stone treatment in anomalous kidney is more demanding, requires more skills and training . the flexible ureterorenoscopy has some problems first the cost but this problem is being now solved by the use of disposable scopes , second the skills it requires , third the possibility of sepsis is higher . to our knowledge most of the studies in the literature are retrospective, carrying some weakness in them. there is no agreed-upon therapeutic method for treatment of stones in anomalous kidney so the investigators will evaluate the role of f-urs in a prospective study.


Eligibility criteria:
inclusion criteria: 1. males and females age above 15 years. 2. renal and ureteric stones either single or multiple wherever the site and site. 3. pelvi-uretreic junction obstruction 4. previous stented ureter. 5. poorly functioning kidney. 6. single functioning kidney. 7. chronic kidney disease patient not on dialysis. 8. previous operation in this kidney. 9. failed eswl. exclusion criteria: 1. not fit for surgery. 2. uncontrolled bleeding diathesis. 3. untreated preoperative urinary tract infection (uti). 4. non function kidney 5. skeletal abnormality
long-term follow-up of anal fistulae in crohn's disease treated with anti-tnfalpha and interest of new mri sequences

Conditions: Anal Fistula; Crohn's Disease

Summary: main purposes of this study are : * analysis of relapse risk of anal fistulae with prospective follow-up of patients undergoing pelvic mri every 6 months for one year. this monitoring also determines if the presence of path of fistulae visible on mri during inclusion visit is associated to increased risk of perianal abscess under infliximab or adalimumab treatment. * evaluation of interest of new magnetic resonance imaging sequences for detection of persistent anal fistulae under infliximab or adalimumab treatment. secondary purposes are: * description of patients with one or more paths of fistulae visible with mri after at least one year of treatment with infliximab or adalimumab administered for anal fistulae and showing a complete healing of fistulae at clinical examination of inclusion visit. * identification of predictive factors (included the presence of paths of fistulae visible with mri during inclusion visit) of relapse of anal fistulae during the 1-year-follow-up after inclusion visit.


Eligibility criteria:
inclusion criteria: * aware and cooperative, giving written consent * crohn's disease diagnosed with clinical, biological, endoscopic and/or radiologic criteria * patient treated with infliximab or adalimumab for perianal fistulizing crohn's disease since at least one year * absence of drainage seton at inclusion * absence of active perianal lesions at inclusion: absence of suggestive symptoms and normal proctologic clinical examination without general anesthesia * patient with mri monitoring for perianal fistulizing crohn's disease exclusion criteria: * patient under juridical protection or without affiliation to social security * refusal or impossibility of giving informed consent * patient not followed-up by mri or having a contraindication for mri, especially the presence of cardiac stimulators or implantable defibrillators, cochlear implants, neurosurgical clips, intra-orbital or encephalic metallic foreign bodies, endo-prostheses placed since at least 4 weeks or osteosynthesis material placed since less than 6 weeks or gadolinium intolerance history * surgery for crohn's disease already planned at inclusion visit, individual participating to another study evaluating efficacy and/or tolerance of medical or surgical treatment for perianal fistulae of crohn's disease * patient treated with anti-tnf for luminal crohn's disease * patient having active perineal lesions
efficacy and safety of abt-874 in subjects with moderate to severe chronic plaque psoriasis

Conditions: Psoriasis

Summary: the purpose of the study is to assess the safety and efficacy of abt-874 in the treatment of moderate to severe chronic plaque psoriasis.


Eligibility criteria:
inclusion criteria: * subject was age 18 or older and in good health (investigator discretion) with a recent stable medical history. * subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis exclusion criteria: * subject had previously received systemic or biologic anti-il-12 therapy * subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid uvb or puva phototherapy * subject is taking or requires oral or injectable corticosteroids * subject considered by the investigator, for any reason, to be an unsuitable candidate for the study * female subject who is pregnant or breast-feeding or considering becoming pregnant
evaluation by mri of anal canal cell carcinoma: is there predictive factor?

Conditions: Anal Carcinoma

Summary: anal canal cell carcinoma is a very rare cancer but well treated. if the morphological test are well established in the initial evaluation, it's not the case of the follow up evaluation particularly by mri.about 1/3 of patient decline with metastatic relapse during the follow up of these patients.it appears that clinical regression seen precociously is a predictive factor of survival without relapse. but there 's no study confirming that point. this context takes us to evaluate if there is a predictive factor in mri to final clinical result.


Eligibility criteria:
inclusion criteria: * patient with anal canal cell carcinoma histologically proved * patient with initial mri and follow up mri in hospital st joseph's radiology yard. * patient for whom a radio chemotherapy treatment decision was taken. exclusion criteria: * patients with already metastatic lesions
echocardiography in septic shock

Conditions: Septic Shock; Severe Sepsis

Summary: background: echocardiography can provide evaluation of right or left ventricular dysfunction and volume status during resuscitation of patients with sepsis and septic shock and guide intravenous vasopressor and fluid therapy. while there are numerous echocardiographic studies regarding cardiac function and volume status in patients with established shock, there are none that describe these during the early resuscitation of septic shock. the study objective is to correlate echocardiographic findings with clinical parameters and net fluid balance measured during the early resuscitation of critically ill patients with sepsis and septic shock. aim 1) correlate echocardiographic findings of cardiac function with physiologic markers in the early hours of resuscitation aim 2) correlate cardiac function and fluid status with clinical outcomes aim 3) evaluate the change in cardiac function over time in patients with sepsis and septic shock aim 4) evaluate long term clinical outcomes for patients with sepsis and septic shock.


Eligibility criteria:
inclusion criteria: - at least 13 years of age sepsis patients: sepsis patients must have 1. suspected or confirmed infection and 2. organ dysfunction as defined by a sofa \>= 2 above baseline (if no baseline data available, sofa assumed to be 0) or septic shock patients: after infusion of 20ml/kg crystalloid or equivalent, septic shock patients must have 1. suspected or confirmed infection and 2. lactate \> 2 mmol/l and 3. receiving vasopressors * enrollment of patients should occur within 8 hours of meeting criteria for severe sepsis or septic shock if it is required that a research only tte be performed in the 0-6 hours after icu admission. if a clinical tte is performed in this timeframe, patients may be enrolled up to 24 hours after icu admission. exclusion criteria: none.

Keywords: septic shock severe sepsis icu
benefit of prophylactic embolization of the splenic salvage

Conditions: Splenic Trauma

Summary: the main objective is to show that splenic embolization improves salvage rate at one month in a population of hemostatically stable closed splenic trauma patients with a high risk of splenectomy


Eligibility criteria:
inclusion criteria: * patients aged over 18 and under 75 years * hemodynamically stable patients (systolic bp ≥ 90 mm hg and no hemorrhagic shock) * suffered a closed splenic trauma within the last 48 hours * a high risk of splenectomy: * reaching spleen moore grade 4 and 5 in the abdominal injected ct or * reaching spleen moore 3 and at least one of the following characteristics: * important hemoperitoneum (when visible in the pelvic area). * severe associated impairment (niss-new injury severity score greater than or equal to 15) * patients volunteering to participate in the study, having signed the consent form or with the agreement of the family if the patient is not capable of giving consent; after adequate information and delivery of the patient and/or family information leaflet. * covered by a social security scheme or beneficiary of such a plan. exclusion criteria: * patients whose usual residence is outside the european economic community * patient with hemodynamic instability (systolic blood pressure \<9 despite resuscitation maneuver) * patient with open splenic trauma * patient with surgical indication excluding the possibility of monitoring splenic trauma * patient with an indication for embolization of a body other than the spleen at the time of inclusion * patient with an indication for splenic embolization as a result of a post-traumatic vascular anomaly (active leakage of contrast agent, pseudoaneurysm or early splenic arteriovenous fistula). * patients aged less than 18 years and ≥ 75 years * patients with a previous spleen disease (tumor, infection, vascular anomaly intrasplenically) * patient with trauma moore grade 1 or 2 * patient with trauma grade moore 5 with total ischemia of the spleen * patients who underwent partial or total splenectomy before inclusion * patient having acquired or innate immune deficiency * all indications not permitting the achievement of embolization * pregnant woman * person deprived of liberty by judicial or administrative decision, person subject to a measure of legal protection. * patient currently participating in a clinical study or having participated in a clinical study in the month preceding the inclusion * patient with a condition or a history of mental or psychiatric disorder or any other factor limiting their ability to participate in an informed manner and to comply with the protocol.

Keywords: splenic rescue; splenectomy
pharmacotherapy in depression with panic spectrum

Conditions: Major Depression

Summary: this research study is being conducted to find out if certain individuals benefit from taking medication for their depression with a low dose of the antidepressant medication zoloft.

researchers at the university of pittsburgh medical center health system are currently recruiting men and women, ages 18 to 60, to examine the effectiveness of the fda-approved medication sertraline (zoloft) for major depression. participants will be randomly assigned to one of two groups. each group will begin and continue taking zoloft at different doses. a physician will follow eligible participants weekly for approximately 12 weeks

Eligibility criteria:
inclusion criteria: * male or female ages 18-60; * current diagnosis of major depression, and a rating of ³15 on the hrs-d-25; - -presence of significant, co-existing panic-agoraphobic spectrum symptoms, * absence of ongoing therapy with psychotropic medications (except for intermittent use of nonbenzodiazepine hypnotics) or willingness to be withdrawn from an ineffective ongoing antidepressant medications * physically healthy, * female participants of childbearing potential must be practicing a medically acceptable form of double-barrier birth control or using oral contraceptives such as birth control pills, implants, or injections; exclusion criteria: * females who are pregnant or breast-feeding; * history of suicide attempt in the 6 months prior to entry, active suicidal ideation, or significant suicide risk; * history of hypersensitivity to or current use of sertraline; * unstable or untreated medical conditions, * participants who do not wish to discontinue current, ineffective antidepressant treatment; * participants who have recently begun psychotherapy (less than 3 months prior to study entry); * diagnosis of current panic disorder, psychosis, substance or alcohol abuse, anorexia, bulimia, dissociative, bipolar disorder, or any other psychiatric or medical illness that would interfere with the best treatment strategy for the potential participant.

Keywords: depression anxiety
lymphocyte and cytokine disturbances in polymyalgia rheumatica

Conditions: Polymyalgia Rheumatica

Summary: pathophysiology of polymyalgia rheumatica (pmr) is ill defined. this study aims at characterizing immunological abnormalities in pmr patients, and to assess the effects of tocilizumab therapy on this abnormalities.

comparison of pmr patients and matched control subjects.

Eligibility criteria:
inclusion criteria: * pmr patient included in the tenor study with samples available exclusion criteria: * patient not included in the tenor study